Market Newsdesk

NEW YORK
, Feb. 5, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.

So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Cassava’s drug prospects and anticipated growth while also minimizing risk from a potential drug failure. Yet, in truth, Cassava’s repeated statements of confidence in simufilam, Cassava’s leading drug candidate, and reliance upon spinning the statistically insignificant data from the Phase 2 study fell short of the reality of simufilam’s potential; Cassava simply did not have a drug that was capable of abating the progression of Alzheimer’s Disease, even when attempting to treat only the mild and moderate cases. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/sava-deadline-sava-investors-have-opportunity-to-lead-cassava-sciences-inc-securities-fraud-lawsuit-302368982.html

SOURCE THE ROSEN LAW FIRM, P. A.

ATLANTA
, Feb. 5, 2025 /PRNewswire/ — Equifax® (NYSE: EFX) today announced that the Equifax Board of Directors declared a quarterly dividend of $0.39 per share, payable on March 14, 2025, to shareholders of record as of the close of business on February 21, 2025. Equifax has paid cash dividends for more than 100 consecutive years.

ABOUT EQUIFAX INC.
At Equifax (NYSE: EFX), we believe knowledge drives progress. As a global data, analytics, and technology company, we play an essential role in the global economy by helping financial institutions, companies, employers, and government agencies make critical decisions with greater confidence. Our unique blend of differentiated data, analytics, and cloud technology drives insights to power decisions to move people forward. Headquartered in Atlanta and supported by nearly 15,000 employees worldwide, Equifax operates or has investments in 24 countries in North America, Central and South America, Europe, and the Asia Pacific region. For more information, visit Equifax.com.

F
OR MORE INFORMATION

[email protected]  

View original content to download multimedia:https://www.prnewswire.com/news-releases/equifax-board-of-directors-declares-quarterly-dividend-302369176.html

SOURCE Equifax Inc.

Foundation supports health and wellbeing research and education across the U.S. 

CINCINNATI
, Feb. 5, 2025 /PRNewswire/ — The Kroger Co. (NYSE:KR), and PepsiCo Inc (NYSE: PEP) today announced their team of chefs took home a Gold Mitt Award for Chef’s Choice in the FMI (Food Marketing Institute) Foundation’s Stir it Up! culinary event held during the FMI Midwinter Executive Conference. Celebrating ten years of National Family Meals Month, and to support food security within our communities, retailers and suppliers were tasked with embracing the theme, “What’s for Dinner? Dishing up New Family Flavors.”

“FMI is a crucial convener of the food industry, which works together to address critical topics like food affordability, safety and accessibility for America’s shoppers,” said Keith Dailey, Kroger’s group vice president of corporate affairs and member of the FMI Foundation board of trustees. “America’s grocery industry enriches lives with nutritious, safe and affordable food and brings joyful and meaningful memories to family mealtimes better than anyone.”

The FMI Foundation, dedicated to delivering research and education to address food safety, health and nutrition concerns, began the Stir it Up! competition nine years ago, bringing retailers and suppliers together to raise millions in support of its vital mission.  

“At PepsiCo we recognize the importance of partnerships and the role they play in improving access to nutrition. We are proud to team up with the FMI Foundation and Kroger to help tackle the issues our local communities are facing and provide families with accessible recipes to enjoy during Family Meal Month,” said Kent Montgomery, Senior Vice President Industry Relations, PepsiCo North America.

Find the complete PepsiCo and Kroger menu here. Filled with unique food and drink offerings inspired by Asian flavors with a Flamin’ Hot® twist. Customers can look forward to many of their favorite products, including:

• Flamin’ Hot® Sushi Platter – available for a limited time only at Kroger Family Stores
• Fresh Dumplings 
• Doritos® Nacho Cheese Flavored Tortilla Chips
• Doritos® Flamin’ Hot® Limón Flavored Tortilla Chips
• Cheetos® Flamin’ Hot® Cheese Flavored Snacks
• Tostitos® Cantina® Thin & Crispy Tortilla Chips
• Private Selection® Chinese Five Spice
• Kroger Brand® Vegetable or Chicken Fried Rice
• Funyuns® Onion Flavored Rings
• Private Selection® Drunken Noodles 
• STARRY®
• Mountain Dew®
• PEPSI ZERO®

For these fresh ingredients and everyday savings, visit Kroger.com or the Kroger app, offering more than $600 in savings available weekly in digital coupons. With more than 30,000 mouthwatering possibilities, customers are a swipe away from inspiration to reality. Kroger is worth it every time.

Customers can get these ingredients and more in-store or through Kroger Pickup and Delivery offering the same fresh products at the same low prices no matter how they shop. Save even more with Boost by Kroger Plus, the membership that can save customers up to $1,100* per year on fuel, exclusive savings, streaming options** and grocery delivery.

* Savings for Boost $99 membership, based on 2 deliveries per week, $91 weekly grocery spend, 13 gallons per fill-up and Fuel Point redemption twice per month. Along with streaming value of $119 based on $9.99 monthly fee for Disney+ Basic (With Ads) and Hulu (With Ads), and $11.99 monthly fee for ESPN+.

** Eligible subs only. Restrictions Apply. See retailer site for details.

About Kroger

At The Kroger Co. (NYSE: KR), we are dedicated to our Purpose: To Feed the Human Spirit™. We are, across our family of companies nearly 420,000 associates who serve over 11 million customers daily through a seamless digital shopping experience and retail food stores under a variety of banner names, serving America through food inspiration and uplift, and creating #ZeroHungerZeroWaste communities. To learn more about us, visit our newsroom and investor relations site.

About PepsiCo

PepsiCo products are enjoyed by consumers more than one billion times a day in more than 200 countries and territories around the world. PepsiCo generated more than $91 billion in net revenue in 2023, driven by a complementary beverage and convenient foods portfolio that includes Lay’s, Doritos, Cheetos, Gatorade, Pepsi-Cola, Mountain Dew, Quaker, and SodaStream. PepsiCo’s product portfolio includes a wide range of enjoyable foods and beverages, including many iconic brands that generate more than $1 billion each in estimated annual retail sales.  

Guiding PepsiCo is our vision to Be the Global Leader in Beverages and Convenient Foods by Winning with pep+ (PepsiCo Positive). pep+ is our strategic end-to-end transformation that puts sustainability and human capital at the center of how we will create value and growth by operating within planetary boundaries and inspiring positive change for the planet and people. For more information, visit www.PepsiCo.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/kroger-and-pepsico-come-together-to-support-food-security-and-uplift-national-family-meals-month-at-fmi-foundation-cook-off-302369154.html

SOURCE The Kroger Co.

Fendt, Massey Ferguson and PTx to showcase Farmer-Focused innovations at February trade shows in California and Kentucky.

DULUTH, Ga.
, Feb. 5, 2025 /PRNewswire/ — AGCO Corporation (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, will exhibit solutions from across its Fendt^®, Massey Ferguson^® and PTx™ brands in February at the 2025 World Ag Expo in Tulare, California, and the National Farm Machinery Show in Louisville, Kentucky. Highlighting the displays will be new products and AE50 award winners, including Fendt’s ErgoSteer™ retrofittable steering joystick and Momentum^® 30-Foot Planter, Massey Ferguson’s S Series tractors, new SB.1436DB Small Square Baler and 2025 compact utility equipment (CUE) lineup, and PTx’s Radicle Agronomics^® automated soil laboratory and OutRun™ autonomous grain cart solution.

World Ag Expo: February 11-13 in Tulare, CA, in Booths AGCO, P56 and Q42
AGCO’s exhibit at World Ag Expo will feature the debut of Massey Ferguson’s new SB.1436DB Small Square Baler, which produces two bales at a time per field pass – twice the output of a single baler that produces 14-by-18-inch bales. Also highlighting the brand’s exhibit will be AE50-winners from across its S Series and 3 Series Specialty tractors, popular hay and forage solutions, a new triple mower model and a special Pit Stop Service Challenge for booth visitors. Additionally, Massey Ferguson will present a new 4700 Series tractor to California Rodeo Salinas as part of the award for being the 2024 Sowing Good Deeds winners. The winning rodeo committee will be present in the Massey Ferguson booth during the show.

Fendt’s exhibits will include the World Ag Expo debut of the award-winning FT600 Vario^® tractor, as well as seven other Vario models. The display will highlight a vineyard-equipped FT200 Vario, which is ideally suited for operations requiring a high level of maneuverability, such as orchards and vineyards. Visitors will also get a special working demonstration of Fendt’s new ErgoSteer solution (another AE50 winner), a joystick option that retrofits onto Fendt 500 to 1000 series tractors for ergonomic, precise and intuitive steering control during field operations.

National Farm Machinery Show: February 12-15 in Louisville, KY, in Booth #7801
AGCO will team up again with AgRevolution™, the company’s rapidly growing dealership in Illinois, Indiana, Kentucky and Ohio, to provide visitors with an expansive exhibit in Louisville. Massey Ferguson will debut its 2025 compact utility equipment (CUE) lineup and the new SB.1436DB Small Square Baler. Fendt’s display will give attendees their first glimpse of the FT600 Vario tractor, as well as the Momentum^® 30-Foot Planter and IDEAL^® 9T combine. AgRevolution product specialists will be on hand in a special technology discussion area that features a FarmerCore™ service truck.

The AGCO booth will feature educational and entertaining sessions from AgRevolution and Acres TV personalities on the AgRev Stage throughout the show. Also appearing in the booth for daily autograph sessions will be winning drivers from the Championship Tractor Pull, which is sponsored by AgRevolution, Fendt and Massey Ferguson. Check this release’s additional downloads for a full schedule of events on the AgRev Stage!

The PTx booth (#4060) will feature Solutions for Every Season from its PTx Trimble™ and Precision Planting^® brands. Farmers will discover how to optimize their existing planters, sprayers and applicators, even if they own mixed fleets. They’ll also learn about field forming and soil sampling solutions that offer precision ag techniques for every aspect of farming operations. Notable exhibits will include Precision Planting’s Radicle Agronomics, SymphonyVision™ vision-based spraying solution and Cornerstone™ planting system, and PTx Trimble’s WM-FieldForm water management solution, OutRun and WeedSeeker^® 2 automatic spot spray system.

To learn more about AGCO’s innovative brands, stop by booths AGCO, P56 and Q42 at World Ag Expo on February 11-13, booths 4060 and 7801 at the National Farm Machinery Show on February 12-15, or visit AGCOcorp.com or AgRev.com.

Fendt, IDEAL, Massey Ferguson, Momentum, PTx, Rogator and Vario are registered trademarks of AGCO. ErgoSteer, FarmerCore, PTx Trimble, OutRun and WeedSeeker are trademarks of AGCO. Precision Planting and Radicle Agronomics are registered trademarks of Precision Planting LLC. CornerStone and SymphonyVision are trademarks of Precision Planting LLC. AgRevolution is a trademark of AgRevolution LLC, a wholly owned subsidiary of AGCO.

About AGCO
AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers value to farmers and OEM customers through its differentiated brand portfolio, including leading brands Fendt®, Massey Ferguson®, PTx and Valtra®. AGCO’s full line of equipment, smart farming solutions and services helps farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $14.4 billion in 2023. For more information, visit www.agcocorp.com.   

View original content to download multimedia:https://www.prnewswire.com/news-releases/agco-to-exhibit-new-solutions-and-ae50-award-winners-at-world-ag-expo-and-national-farm-machinery-show-302369043.html

SOURCE AGCO Corporation

LOS ANGELES
, Feb. 5, 2025 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with losses related to Nextracker Inc. (“Nextracker” or the “Company”) (NASDAQ: NXT) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEXTRACKER INC. (NXT), CLICK HERE BEFORE FEBRUARY 25, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

 
What Is The Lawsuit About?
The complaint filed alleges that, between February 1, 2024 and August 1, 2024, Defendants failed to disclose to investors: (1) that the impact of project delays on Nextracker’s business, financial results, and prospects was far more severe than represented to investors; (2) that permitting and interconnection delays had materially impaired Nextracker’s ability to convert backlog into revenue at historical conversion rates; (3) that Nextracker had been unable to offset the negative impact from project delays through increased client demand and the purported ability to pull forward its other projects in the manner represented by defendants; (4) that Nextracker did not possess the competitive advantages which purportedly shielded it from industry-wide headwinds or the ability to effectively offset the adverse effects of project delays as claimed by defendants; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz,
Telephone: 310-914-5007
Email: [email protected]
Visit our website at: www.frankcruzlaw.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nextracker-inc-nxt-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302368465.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

DENVER
, Feb. 5, 2025 /PRNewswire/ — Summit Materials, Inc. (NYSE: SUM) (“Summit,” “Summit Materials” or the “Company”), a leading producer of aggregates and cement, today announced that the Company has obtained all requisite stockholder approvals in connection with the proposed acquisition by Quikrete Holdings, Inc. (“Quikrete”). Summit will disclose the final, certified voting results on a Form 8-K with the U.S. Securities and Exchange Commission (“SEC”).

As previously announced, the proposed transaction is expected to close within the first quarter of 2025, subject to the satisfaction of remaining customary closing conditions. Upon completion of the transaction, Summit will become a privately held subsidiary of Quikrete and its common stock will no longer be traded on the NYSE.

Advisors
Morgan Stanley & Co. LLC and Evercore are acting as financial advisors to Summit, and Davis Polk & Wardwell LLP is acting as legal advisor. Wells Fargo is acting as exclusive financial advisor to Quikrete, and Troutman Pepper Locke LLP and Covington & Burling LLP are acting as legal counsel. Wells Fargo has provided a debt financing commitment for the Merger.

About Summit Materials, Inc.
Summit Materials is a market-leading producer of aggregates and cement with vertically integrated operations that supply ready-mix concrete and asphalt in select markets. Summit is a geographically diverse, materials-led business of scale that offers customers in the United States and British Columbia, Canada high quality products and services for the public infrastructure, residential and non-residential end markets. Summit has a strong track record of successful acquisitions since its founding and continues to pursue high-return growth opportunities in new and existing markets. For more information about Summit Materials, please visit www.summit-materials.com.

About Quikrete Holdings, Inc.
Quikrete Holdings, Inc. (Quikrete) is a privately owned family business founded in 1940. It is a leading building materials company based in Atlanta, Georgia. From the original yellow bag of premixed concrete, today Quikrete’s portfolio of brands includes Quikrete, Spec Mix, Rinker Materials, U.S. Pipe, Contech Engineered Solutions, Keystone Hardscapes, Pavestone, Custom Building Products, QPR, and other leading brands. The products produced by the collection of brands include packaged cementitious products, pavers, retaining wall systems, masonry units, tile grouts and thin sets, concrete pipe, box culverts, corrugated metal pipe, ductile iron pipe, engineered storm water systems, structural precast, and steel pedestrian and vehicular bridges. The company services the US and Canadian commercial construction, residential, and infrastructure markets. This broad array of products and expertise allows Quikrete to provide nearly every product required for most any type of construction project.

Cautionary Statement Regarding Forward-Looking Statements
This communication includes “forward-looking statements” within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include all statements that do not relate solely to historical or current facts, and you can identify forward-looking statements because they contain words such as “believes,” “expects,” “may,” “will,” “should,” “seeks,” “intends,” “trends,” “plans,” “estimates,” “projects” or “anticipates” or similar expressions that concern our strategy, plans, expectations or intentions. All statements made relating to our estimated and projected earnings, margins, costs, expenditures, cash flows, growth rates and financial results are forward-looking statements. Such forward-looking statements include but are not limited to statements about the Merger, including statements that are not historical facts. These forward-looking statements are subject to risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, it is very difficult to predict the effect of known factors, and, of course, it is impossible to anticipate all factors that could affect our actual results. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that the results or conditions described in such statements or our objectives and plans will be realized. Important factors could affect our results and could cause results to differ materially from those expressed in our forward-looking statements, including but not limited to the factors discussed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023, and Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2024, each as filed with the SEC, and any factors discussed in the section entitled “Risk Factors” in any of our subsequently filed SEC filings; and the following:  (i) the occurrence of any event, change, or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive transaction agreement between the Company and Purchaser, including in circumstances requiring the Company to pay a termination fee; (ii) potential litigation relating to the Merger that could be instituted against the parties to the definitive transaction agreement or their respective directors or officers, including the effects of any outcomes related thereto; (iii) the possibility that the Merger does not close when expected or at all because required regulatory or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all; (iv) reputational risk and potential adverse reactions of customers, employees or other business partners and the businesses generally, including those resulting from the announcement of the Merger; (v) the risk that any announcements relating to the Merger could have adverse effects on the market price of the Company’s common stock; (vi) significant transaction costs associated with the Merger; and (vii) the diversion of management’s attention and time from ongoing business operations and opportunities on Merger-related matters. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements. Any forward-looking statement that we make herein speaks only as of the date of this communication. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law.

All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements. Any forward-looking statement that we make herein speaks only as of the date of this communication. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law.

Contacts:

Andy Larkin

VP, Investor Relations
Summit Materials, Inc.
[email protected] 
720-618-6013

Jim Barron/Benjamin Spicehandler/Danielle Berg
FGS Global
[email protected]  

Patrick Lenow

Vice President, Marketing & Communications
Quikrete Holdings, Inc.
404-634-9100
[email protected]  

View original content to download multimedia:https://www.prnewswire.com/news-releases/summit-materials-announces-stockholder-approval-of-quikrete-transaction-302369068.html

SOURCE Summit Materials, Inc.

LOS ANGELES
, Feb. 5, 2025 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with losses related to BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BIOAGE LABS, INC., CLICK HERE BEFORE MARCH 10, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

What Is The Lawsuit About? 
The complaint filed alleges that, between pursuant and/or traceable to the Registration Statement issued in connection with the Company’s September 2024 initial public offering, Defendants failed to disclose to investors: (1) the potential for liver transaminitis in any of its previous clinical Phase 1 trials and various preclinical tox studies; (2) potential safety concerns with the Company’s ongoing STRIDES clinical trial; (3) that, as a result, the Company overstated the likelihood the ongoing STRIDES study would be completed; (4) that, as a result, the Company overstated the potential of a second Phase 2 clinical trial combining azelaprag and semaglutide to treat obesity in individuals ages 18 years and older; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bioage-labs-inc-bioa-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302368471.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

LOS ANGELES
, Feb. 5, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against FTAI Aviation Ltd. (“FTAI” or the “Company”) (NASDAQ: FTAI).

IF YOU SUFFERED A LOSS ON YOUR FTAI INVESTMENTS, CLICK HERE
BEFORE MARCH 18, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, between July 23, 2024 and January 15, 2025, Defendants failed to disclose to investors: (1) the Company reported one-time engine sales as Maintenance Repair & Overhaul revenue when FTAI only performs limited repair and maintenance work on the engine assets sold; (2) FTAI presents whole engine sales as individual module sales, thereby overstating sales and demand; (3) the Company depreciates engines that are not on lease, which misleadingly lowers the reported cost of goods sold and inflates EBITDA; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 

Glancy Prongay & Murray LLP,  
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067

Charles Linehan

Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ftai-aviation-ltd-ftai-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302368466.html

SOURCE Glancy Prongay & Murray LLP

EDINBURGH, Scotland
, Feb. 5, 2025 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it will change its ratio of its American Depositary Shares (“ADSs”) to ordinary shares from one (1) ADS representing two hundred (200) ordinary shares to one ADS representing four thousand (4,000) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change is expected to become effective on February 10, 2025, U.S. Eastern Time.

The ADS Ratio Change will have the same effect as a 1-for-20 reverse ADS split for the ADS holders. The ADS Ratio Change will not impact the Company’s underlying ordinary shares, and no ordinary shares will be issued or canceled in connection with the ADS Ratio Change. 

On the Effective Date, holders of the ADSs will be required to surrender and exchange every twenty (20) ADSs, held for one (1) new ADS. The Bank of New York Mellon, as the depositary bank for the Company’s ADS program (the “Depositary”), will arrange for the exchange. The ADSs will continue to be traded on Nasdaq Capital Market under the symbol “TCBP.”

No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes, and expenses) will be distributed to the applicable ADS holders by the Depositary.

As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally. However, the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be proportionally equal to or greater than the previous’ ADS trading price before the change.

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.

TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company’s proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.

Forward-Looking Statements for TC BioPharm

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company’s intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management’s current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company’s Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date of this press release. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-to-implement-ads-ratio-change-302369141.html

SOURCE TC BioPharm